Thanks, Brian. this And thanks everyone for afternoon. us joining
of to clinical our to stage of strong while therapies. delivering deliver is to importantly, currently stakeholders, straightforward beyond existing strategy four purposeful patient year, pipeline through our advance the benefit foundation our we've value mission ultimate achieved building and last a Over candidates, executed what oncology on to a continue
go prepared each milestones and programs, the I'll our few of plans upcoming my for including As you through quarters. on update remarks, I the next
Let's so is delta potential class of the we inhibitor as evidence the for the far ME-XXX based best in start clinical emerging malignancies. on which with treatment B-cell PIX believe
Please such currently recall two approval an as application the that trial clinical a studies, have relapse evaluating with with a Phase a we a as X support combination with lymphoma that as by in zanubrutinib strategy being Xb to study intended marketing investigational Beijing. for evaluating refractory primarily BTK developed an is follicular inhibitor Rituxan FDA, Phase well or ongoing accelerated ME-XXX patients to agents of
is for significant treating in potential potential other classes that and pathways, exceed I B-cell matches for are pathways. delta targeting given signaling And of may that found delta a target hold PIX malignancies. surprising believe at general, delta such drug is PIX these of inhibitors. even the This crossroads the B-cell treatment B-cell as several PIX clinically validated of inhibitors disease BTK is the other actually not the B-cell
historically, been This inhibitor delta studies However, biologic by the utility. hinder with of of PIX limiting potential next better an for restricting a inhibition, clinical candidate generation properties toxicities, that the maximize PIX while pharmaceutical their delta has those their clinical can development challenged toxic limiting opportunity class utility. presents that
chapter results treat unique opportunity therapies inhibitors, approved large others of part and that in malignancies. have combination characteristics in are to new utility ME-XXX we of delta distinct structure believe B-cell in open molecular FDA we particularly is pharmacodynamic from the This PIX development. delta ME-XXX, which of the in in to inhibitors, because other with With a the
XX tissues distribution throughout oral is target body accumulation, administration. and by prolonged ME-XXX once characterized cellular suitable binding, daily preferential a for hour half-life significant the
potential to class of the within inhibitors. attributes believe We and the PIXK are differentiation clinical important these utility
other of with therapies dosing combination to exploration ME-XXX's PIX immune dosing the related benefit, as intermittent toxicities we clinical such while agents. investigational as agents, Specifically, which maintain or either other common or properties flexible believe an to potential allow in regimens, monotherapy the has delta schedule, a in minimizing
versus or ME-XXX once administration of followed by XXX two the the On by daily schedule daily where placebo administered is weeks, first followed eight intermittent XX continuous day for a days schedule of the daily. XX administered seven cycles for once is days cycle,
the maturation today, either generation XXX for believe on of the or view evidence delta ME-XXX inhibitors. ME-XXX on schedules, as PIX now Based there's data continuous strong of which patients potentially we next this includes with treated intermittent over differentiated a our
as Recently, we the reduction intermittent adverse in less. to XX% rate the but and XXXX XXXX schedule, of response patients demonstrating events ICML levels the patients that presented such on and overall colitis to special of on follicular the and or data similar a in achieved at CLL an ASCO two-thirds that schedule continuous nearly with diarrhea meetings, interest,
emerging profile This highlights the and development is ASCO we a schedules in data. the this the factor intermittent observed clinical program. importance And key of dosing of key a ICML in the believe part
that inhibition delta while recovery catalyst being important a the In the intermittent consistent B-cell allowing PIXK sufficient an of periphery. events this interest see support data, the intermittent likely cells, delta in provide basis schedule in target we rationale strong with for T-regulatory as scientific potentially of adverse the the for intermittent for the and tumors, schedule clinical schedule, special B-cell the for dosing
submit for Phase a as data with around to adults follicular we a accelerated beginning therapies, the We intend relapse application refractory systemic least chemotherapy at FDA. results monotherapy of clinical treatment prior initiated CDXX the with of and approval these on the antibody. evaluating including trial of anti X lymphoma to support of failure XXXX, calendar to an the Based ME-XXX marketing after two
endpoint in both next evaluating The the approval an regulatory continuous We this dosing around through for Phase of trial the represents X third the the will intermittent to be primary marketing enrollment in is be XXX the time is approval response the Phase completing randomized anticipate to study efficacy therapy. year. line follicular this regimens. and Approximately rate X trial opportunity an will FDA path sometime accelerated and patients objective for mechanism. expedited The lymphoma
line represents follicular need important an a opportunity broader lymphoma to unmet and third opportunity. commercially, are medical meet attracted an targeting we is While
the in malignancy study, the treatment are of such we further a intermittent the B-cell for other of schedule Xb as indications. continuing Phase combination part to As approach explore
Urso, Officer, opportunity activities are related the our combination and expanded and leads ME-XXX over plans our since with around year development our to treatments some our will of partnering who last David to moving forward. the business our they speak Chief strategic Operating work efforts these
And with that, I'll turn it to over David.
